Press release

Please find below Nanobiotix’s latest press releases.
169 result
Nanobiotix files registration statement for proposed initial public offering in the United States
Nanobiotix announces two new phase II trials evaluating NBTXR3 in combination with anti-PD-1 for the treatment of head and neck cancer
Nanobiotix announces positive new pre-clinical data suggesting radioenhancer NBTXR3 could have a significant impact in immunotherapy
Nanobiotix announces positive first clinical data showing conversion of anti-PD-1 non-responders to responders with radioenhancer NBTXR3
Nanobiotix provides update on global clinical development plan for first-in-class radioenhancer NBTXR3
Nanobiotix announces third quarter 2020 revenue
Nanobiotix announces four presentations at the Society for Immunotherapy of Cancer (SITC) 35th anniversary annual meeting
Nanobiotix announces first patient injected with NBTXR3 in pancreatic cancer and safe to proceed notifications for two additional trials from U.S. FDA
Nanobiotix announces half-year financial statements as at June 30, 2020
Update to the Nanobiotix press release dated july 28, 2020

Update to the Nanobiotix press release dated july 28, 2020

The following pages contain information regarding the [potential] capital increase of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.
Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.
Sorry
Not for access within the United States, Canada, Japan or Australia
Nanobiotix successfully raises approximatively €20 million in placement of ordinary new shares with US and european investors

Nanobiotix successfully raises approximatively €20 million in placement of ordinary new shares with US and european investors

The following pages contain information regarding the [potential] capital increase of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.
Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.
Sorry
Not for access within the United States, Canada, Japan or Australia
Nanobiotix launches a placement

Title

The following pages contain information regarding the [potential] capital increase of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.
Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.
Sorry
Not for access within the United States, Canada, Japan or Australia
Nanobiotix announces revenue for second quarter 2020 and first half year 2020
Nanobiotix receives feedback from US FDA to advance phase III head and neck cancer study design and CMC development plan for NDA
Nanobiotix spinoff Curadigm validates novel nanoprimer technology in RNA therapeutics
Nanobiotix announces positive first results from phase I expansion in locally advanced head and neck cancer at ASCO 2020
Publication of the 2019 Universal Registration Document
Nanobiotix announces first phase I trial with NBTXR3 in pancreatic cancer is safe to proceed per US FDA
Nanobiotix announces first quarter 2020 revenues
Nanobiotix provides updates on clinical development continuity in the context of the Covid-19 crisis
Nanobiotix 2019 Annual results
Nanobiotix 2019 Q4 and annual revenues
Scientific Clinical | Nanobiotix announces Fast Track designation granted by U.S. FDA for investigation of first-in-class NBTXR3 in Head and Neck cancer
Scientific Clinical | Nanobiotix announces plan for global phase III Head and Neck cancer registration trial along with overall development update
Corporate | Nanobiotix receives the 2019 Prix Galien award for first-in-class Hensify
Scientific Clinical | Nanobiotix announces new results from pre-clinical immuno-oncology study at SITC 2019
Financial | Nanobiotix announces third quarter 2019 revenue
Scientific Clinical | Phase I study results show first-in-class NBTXR3 could present as a valuable option for patients with hepatocellular carcinoma or liver metastasis
Financial | Nanobiotix announces half year financial statements of june 30, 2019
Financial | Nanobiotix announces second quarter 2019 revenue
Scientific Clinical | Nanobiotix announces publication of phase III soft tissue sarcoma data for first-in-class NBTXR3 in the Lancet Oncology
Corporate | Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval
Nanobiotix launches a placement
Corporate | Nanobiotix appoints new chief medical officer as the company evolves after achievement of european market approval
Scientific Clinical | Nanobiotix announces the launch of Curadigm : A new nanotechnology platform for healthcare
Financial | Nanobiotix announces first quarter 2019 revenue
Financial | Laurent Levy, CEO, increases stake in Nanobiotix's capital
Nanobiotix raises approximately EUR 29.5 million in placement of ordinary new shares

Nanobiotix raises approximately EUR 29.5 million in placement of ordinary new shares

The following pages contain information regarding the placement of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.
Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.
Sorry
Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.
Nanobiotix raises approximately EUR 29.5 million in placement of ordinary new shares
Scientific Clinical | Nanobiotix announces first ever radioenhancer to receive european market approval
Scientific Clinical | Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer
Scientific Clinical | Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback
Financial | Nanobiotix 2018 Annual Results
Financial | Nanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank
Financial | Nanobiotix 2018 Q4 and annual revenues
Financial | Nanobiotix Plans to Conduct Registered Public Offering in the United States
Scientific Clinical | Nanobiotix and MD Anderson Cancer Center announce a large-scale, comprehensive clinical collaboration on NBTXR3
Financial | Nanobiotix revenues for the 3rd quarter of 2018
Scientific Clinical | NANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMO
Financial | Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment Bank
Scientific Clinical | Nanobiotix to present positive results from its phase II/III clinical trial of NBTXR3 in patients with STS and other ongoing phase I/II trials at ESMO and ASTRO
Scientific Clinical | Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018
Financial | Nanobiotix half year results for the six months ended June 30, 2018
Financial | Nanobiotix signs a 40 M€ non-dilutive financing agreement with the European Investment Bank
Financial | NANOBIOTIX revenue for the 2nd quarter of 2018
Scientific Clinical | Nanobiotix announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3
Financial | NANOBIOTIX’ Management statement on recent share price variation
Financial | NANOBIOTIX revenue for the 1st quarter of 2018
Scientific Clinical | Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers
Financial | NANOBIOTIX selected to enter Euronext’s Tech 40 Label
Scientific Clinical | AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway
Scientific Clinical | The University of Texas MD Anderson Cancer Center and Nanobiotix have an agreement to run immunotherapeutic pre-clinical research in lung cancer combining NBTXR3 & Nivolumab
Financial | Nanobiotix 2017 Annual Results
Financial | Nanobiotix 2017 Q4 and annual revenues
Scientific Clinical | Nanobiotix presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at American Society Of Clinical Oncology Gastroin­testinal Annual Meeting
Scientific Clinical | Nanobiotix partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers
Nanobiotix launches a private placement
Corporate | Nanobiotix: 2017 review and 2018 expected milestones
Scientific Clinical | FDA approves Nanobiotix’s first Immuno-Oncology trial
Financial | Nanobiotix revenues for the 3rd quarter of 2017
Scientific Clinical | Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting
Scientific Clinical | Nanobiotix provides update on the global development of its lead product NBTXR3
Financial | Nanobiotix successfully completes approximately eur 27.2 million placement of new shares
Financial | Nanobiotix launches capital increase by means of an accelerated bookbuild offering

Nanobiotix launches capital increase by means of an accelerated bookbuild offering

The following pages contain information regarding the placement of Nanobiotix. For regulatory reasons, the distribution of the content of such information is restricted. Consequently, please fill out the fields below to access such information.
Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.
Sorry
Access to this information is restricted to persons who are located outside the United States, Canada, Japan and Australia.
Scientific Clinical | Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma
Scientific Clinical | Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S.
Financial | Nanobiotix half year results for the six months ended 30 June 2017
Financial | Nanobiotix revenues for the 2nd quarter of 2017
Scientific Clinical | NANOBIOTIX: new translational data presented at ASTRO, NCI AND SITC’S Immunotherapy Workshop
Scientific Clinical | NANOBIOTIX: promising data from phase I/II Head and Neck cancer trial with NBTXR3 presented at the American Society of Clinical Oncology’s Annual Meeting
Scientific Clinical | NANOBIOTIX announces first positive Human data showing that NBTXR3 could become a backbone in Immuno-Oncology
Financial | Nanobiotix revenue for the 1st quarter of 2017
Financial | Nanobiotix: 2016 Annual Results
Financial | Nanobiotix successfully completes approx. EUR 25.1 million private placement of new shares
Corporate | Nanobiotix expands its clinical development in Head and Neck cancer and Immuno-Oncology ; new clinical data to be presented at ASCO
Scientific Clinical | NANOBIOTIX: the Independent Data Monitoring Committee recommends the continuation of the ongoing phase II/III trial of NBTXR3 in Soft Tissue Sarcoma
Scientific Clinical | Nanobiotix to present preclinical data on nanoparticle radioenhancer NBTXR3 at the AACR Annual Meeting 2017
Financial | Nanobiotix 2016 Q4 and annual revenues
Corporate | Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer
Corporate | Nanobiotix: 2016 review and 2017 anticipated milestones
Scientific Clinical | Nanobiotix reports positive Phase I/II preliminary data on feasibility and safety of NBTXR3 in liver cancers trial
Scientific Clinical | Nanobiotix Provides Update on Global Development of Lead Product NBTXR3
Financial | Nanobiotix revenue for Q3 2016
Scientific Clinical | Nanobiotix presents NBTXR3 preclinical data demonstrating its potential usage as in situ vaccine for cancer
Scientific Clinical | Nanobiotix’s partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia
Corporate | Nanobiotix Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development and Director of Investor Relations
Financial | Bpifrance grants Nanobiotix a 2M€ interest-free loan to support final development stage of lead product, NBTXR3
Corporate | Nanobiotix announces submission for first market approval of lead product NBTXR3 in Europe
Financial | Nanobiotix half year results for the six months ended 30 June 2016
Financial | Nanobiotix revenue for Q2 2016
Scientific Clinical | Nanobiotix reports successful results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer
Financial | Nanobiotix announces exercise of warrants by Capital Venture International
Corporate | Nanobiotix receives US$1m milestone payment from PharmaEngine
Scientific Clinical | Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology
Financial | Revenue for the 1st quarter of 2016
Financial | Nanobiotix 2015 Annual Results
Financial | Nanobiotix completes a EUR 21 million private placement
Scientific Clinical | FDA approved Investigational New Drug for NBTXR3 in a new clinical study in prostate cancer
Financial | Nanobiotix Revenue Q3 2015
Scientific Clinical | Nanobiotix’s Soft Tissue Sarcoma pivotal trial progressing well as planned: already 7 countries and 29 sites opened
Financial | Nanobiotix Half Year Results for the period ended 30 June 2015
Financial | Nanobiotix Revenue Q2 2015
Scientific Clinical | Nanobiotix starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3
Scientific Clinical | Nanobiotix reports positive preliminary results in Head and Neck cancer Phase I/II clinical trial with NBTXR3
Financial | Nanobiotix Revenue Q1 2015
Scientific Clinical | Nanobiotix expands Soft Tissue Sarcoma pivotal clinical trial across Europe and beyond, according to plan
Financial | Nanobiotix 2014 Annual Results
Corporate | Nanobiotix appoints its Manufacturing Partner, CordenPharma : another step towards commercialization
Financial | Nanobiotix 2014 Q4 and annual revenues
Corporate | Professor Robert Langer joins Nanobiotix as Scientific Advisor
Financial | Nanobiotix secures financing from a major US investor, to address the US market
Financial | Nanobiotix 2014 Q3 Revenues
Scientific Clinical | Nanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe
Financial | Nanobiotix reaches the second milestone payment of Bpifrance dedicated to NBTXR3 development in liver cancers
Scientific Clinical | PharmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific
Corporate | Nanobiotix expands operations into the USA
Financial | Nanobiotix Half year Results for the period ended 30 june 2014
Financial | Nanobiotix 2014 Q2 Revenues
Financial | Nanobiotix joins the CAC® PME Index
Scientific Clinical | Nanobiotix presents successful Phase I results for its lead nanomedicine product NBTXR3 at ASCO
Financial | Nanobiotix Revenue Q1 2014 and new composition shareholding
Corporate | Nanobiotix appoints Thierry Otin as Head of Manufacturing and supply
Financial | Nanobiotix 2013 Annual Results
Scientific Clinical | Nanobiotix selected to present data from NBTXR3 clinical trial at ASCO
Scientific Clinical | Nanobiotix sees Clinical Advance in Soft Tissue Sarcoma Pilot Trial with Lead Product, NBTXR3
Financial | Nanobiotix 2013 annual revenues
Corporate | Nanobiotix strengthens its Supervisory Board
Corporate | Nanobiotix 2014 Review, 2015 Anticipated Milestones and Financial Calendar
Corporate | Nanomedicine Map reveals the European landscape and potential
Scientific Clinical | Nanobiotix strengthens its NanoXray pipeline with the launch of NBTX-TOPO development, the first nanotherapeutic with embedded radar
Financial | Nanobiotix Q3 Revenue 2013
Corporate | Nanobiotix honored at the INVESTOR AWARDS 2013 in the “Young Talent” category
Corporate | Nanobiotix strengthens its management team
Financial | Nanobiotix Half Year Results for the period ended 30 June 2013
Financial | Nanobiotix 2013 Q2 revenue
Corporate | Nanobiotix announces €2.8 million grant from bpifrance to accelerate development of NBTXR3 in a third new indication
Scientific Clinical | Nanobiotix announces the selection of its second NanoXray product, NBTX-IV and a collaboration with the NCI for development
Scientific Clinical | Nanobiotix receives approval from ANSM to start new Clinical Trial with Lead Product NBTXR3
Scientific Clinical | Nanobiotix’s NBTXR3 Achieves Clinical Milestone Reaching Proof-Of- Concept in Phase I Trial of Soft Tissue Sarcoma
Financial | Nanobiotix 2013 Q1 revenues
Financial | Nanobiotix 2012 Annual Results
Corporate | Dr. Laurent Levy, CEO of Nanobiotix, receives the UB Entrepreneurship Award from the University at Buffalo, SUNY
Corporate | Nanobiotix Selected to Present at Future Leaders in the Biotech Industry Conference
Corporate | Nanobiotix appoints Dr Alain Herrera to the Supervisory Board
Financial | Nanobiotix 2012 revenues
Financial | 2013 Financial agenda
Corporate | Nanobiotix 2013 Review Significant Corporate and Clinical Progress
Corporate | Laurent Levy, CEO Nanobiotix, elected Vice-Chairman of the ETPN
Scientific Clinical | Phase I Independent Data Monitoring Committee confirms good safety of NBTXR3 in the first group of patients with advanced STS
Corporate | Nanomed2020 intends to bring more nanomedicine products to European patients
Corporate | PharmaEngine and Nanobiotix Sign Asia-Pacific Exclusive License and Collaboration Agreement for NBTXR3
Scientific Clinical | Nanobiotix and Thomas Jefferson University Start Research Collaboration
Corporate | Nanobiotix appoints Dr. Bernd Muehlenweg as a member of the Executive Board
Financial | Nanobiotix receives 1 million euro from OSEO
Scientific Clinical | Nanobiotix Starts Clinical Trial with Lead Product NBTXR3
Corporate | Nanobiotix announces changes to the non-executive board
Corporate | Nanbiotix welcomes Dr Bernd Mühlenweg as Head of Business Development
Corporate | Nanobiotix welcomes Laurent Condomine on board
English